Static

Millions of Americans are not taking their GLP-1 drugs as prescribed

First reported by Ars Technica ·

The signal ●○○○ Compiled by AI from Ars Technica, the single source so far
Why you might care

The cost and access barriers for GLP-1 medications mean that many users are altering their prescriptions, potentially compromising treatment effectiveness and safety.

What happened

Millions of Americans are not taking GLP-1 medications, including popular drugs for diabetes and weight loss like Ozempic and Wegovy, as prescribed. A CDC study of over 8,000 adults found that approximately 27 million Americans, or 9.8 percent of the adult population, used GLP-1 medications in 2025. Among these users, nearly half (44 percent) reported modifying their use by skipping doses, delaying refills, or using lower doses. The primary reasons cited for these modifications were cost and accessibility issues, particularly for younger adults. Furthermore, over 23 percent of users were taking compounded versions of these drugs, which are not FDA-approved and may carry higher risks due to potential manufacturing errors or contamination. These compounded versions are often marketed in ways that mislead consumers into believing they are FDA-approved.

What it means

The widespread non-adherence to GLP-1 prescriptions, driven by cost and access, highlights a significant public health challenge. The reliance on unapproved compounded versions, often marketed misleadingly, raises serious questions about drug safety and efficacy in real-world settings. This trend could necessitate new regulatory approaches or clearer consumer guidance to ensure patient well-being amidst a rapidly growing market for these powerful medications.

The market for GLP-1 drugs is clearly bifurcated between approved, high-cost medications and a more accessible, but less regulated, compounded segment. This dynamic is likely to persist, with patient advocacy groups and potentially some providers pushing for more affordable access options. Future research into the safety and effectiveness of these modified and compounded uses will be crucial for informing clinical guidelines and protecting public health from unmonitored medication practices.

AI-written summary. May contain errors.

Millions